0001209191-23-032034.txt : 20230524
0001209191-23-032034.hdr.sgml : 20230524
20230524210018
ACCESSION NUMBER: 0001209191-23-032034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230522
FILED AS OF DATE: 20230524
DATE AS OF CHANGE: 20230524
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Binder Steven B.
CENTRAL INDEX KEY: 0001712601
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50865
FILM NUMBER: 23955723
MAIL ADDRESS:
STREET 1: 30930 RUSSELL RANCH ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MANNKIND CORP
CENTRAL INDEX KEY: 0000899460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133607736
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 CASPER STREET
CITY: DANBURY
STATE: CT
ZIP: 06810
BUSINESS PHONE: 818-661-5000
MAIL ADDRESS:
STREET 1: 1 CASPER STREET
CITY: DANBURY
STATE: CT
ZIP: 06810
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-22
0
0000899460
MANNKIND CORP
MNKD
0001712601
Binder Steven B.
1 CASPER STREET
DANBURY
CT
06810
0
1
0
0
Chief Financial Officer
0
Common Stock, $.01 Par Value
2023-05-22
4
A
0
400000
4.79
A
1113539
D
Common Stock, $.01 Par Value
2023-05-22
4
F
0
227405
4.79
D
886134
D
Common Stock, $.01 Par Value
2023-05-24
4
S
0
47810
4.675
D
838324
D
A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 600,000 shares. The acquisition of 200,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020.
Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units.
Transaction occurred pursuant to Rule 10B5-1 Plan.
/s/ Steven B. Binder
2023-05-24